Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD6918 + pemetrexed
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
AZD6918 + pemetrexed is an investigational combination therapy studied in oncology, specifically for its potential in treating advanced or metastatic non-small cell lung cancer (NSCLC). AZD6918 is an experimental drug developed by AstraZeneca and tested in combination regimens with established chemotherapeutics, including pemetrexed. Pemetrexed is a folate antimetabolite chemotherapy agent that inhibits multiple enzymes involved in folate metabolism, thus inhibiting DNA synthesis and cell replication. The rationale for combining AZD6918, whose detailed mechanism is not fully described in public sources but is being developed by AstraZeneca, with pemetrexed is to enhance antitumor efficacy by targeting complementary pathways in cancer cell proliferation[3][1][2].
- Other names
- AZD6918 and pemetrexedAZD-6918 and pemetrexedAZD 6918 and pemetrexedAZD6918 combinationAZD-6918 combinationAZD 6918 combinationAZD6918 plus pemetrexedAZD-6918 plus pemetrexedAZD 6918 plus pemetrexed
02
Targets
NTRK3 (Tropomyosin receptor kinase C)GART (GAR transformylase)NTRK2 (Tropomyosin-related kinase receptor type B)DHFR (Dihydrofolate reductase)NTRK1 (Tropomyosin-related receptor kinase A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on AZD6918 + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD6918 + pemetrexed.